Lisinopril FDA Approval History: Original NDA, Label Changes, and Post-Market Safety Record

What Is Lisinopril and Why Does Its Regulatory History Matter?

Lisinopril is a long-acting, orally active ACE inhibitor approved for three distinct cardiovascular indications. Its regulatory history is one of the most thoroughly documented among any antihypertensive, covering nearly four decades of label revisions, post-market safety signals, and landmark outcomes trials. Clinicians prescribing it today inherit the full weight of that record.

The Drug Itself

Lisinopril is the lysine analogue of enalaprilat. Unlike enalapril, it does not require hepatic conversion to an active metabolite, it is active as absorbed. Half-life runs approximately 12 hours, supporting once-daily dosing. Renal excretion is the sole elimination route, which directly shapes the dosing adjustments seen in every version of the label since 1987.

Why Regulatory Literacy Matters for Prescribers

The FDA label is a living legal document. Changes to contraindications, warnings, and dosing tables reflect accumulated real-world evidence that clinical trial data alone could not capture. The shift from a narrative pregnancy warning to a full boxed warning in 2003, for example, changed prescribing behavior in women of reproductive age far more than the original approval text had. Knowing when each change occurred and why allows clinicians to explain risk to patients accurately rather than reciting outdated language.

Original FDA Approval: December 1987

Lisinopril's path to approval was relatively straightforward by late-1980s standards. The FDA accepted two separate New Drug Applications (NDAs): NDA 019777 for Prinivil (Merck) and NDA 019898 for Zestril (ICI Pharmaceuticals, later AstraZeneca). Both received approval on December 19, 1987, for the treatment of hypertension.

The NDA Submission Package

The key clinical data submitted to FDA consisted of dose-ranging studies and double-blind, placebo-controlled trials demonstrating statistically significant reductions in seated diastolic blood pressure at doses of 10 mg to 40 mg once daily. Renal function data drove the initial dosing guidance for patients with creatinine clearance below 30 mL/min, a threshold that has remained relatively stable through subsequent label revisions.

What the 1987 Label Said

The 1987 label identified the primary indication as hypertension and specified that lisinopril could be used as monotherapy or combined with thiazide diuretics. Contraindications included known hypersensitivity to ACE inhibitors and a history of angioedema related to prior ACE inhibitor therapy. The pregnancy category at that time was C in the first trimester and D in the second and third trimesters, a distinction that would later be collapsed into a unified boxed warning.

Expansion of Indications: 1991 and 1993

Heart Failure Approval (1991)

In 1991, Merck received supplemental NDA approval for Prinivil in heart failure, specifically as adjunctive therapy in patients not responding adequately to diuretics and digitalis. The key data cited in the supplemental submission included the CONSENSUS trial, in which enalapril (a closely related ACE inhibitor) reduced all-cause mortality by 40% at 6 months in severe heart failure. Lisinopril's own dose-response data in NYHA class II-IV patients supported the extrapolation. The approved dosing range for heart failure started at 2.5 mg and could be titrated to 40 mg once daily.

Acute Myocardial Infarction Approval (1993)

The GISSI-3 trial (N=19,394) provided the primary evidence for the 1993 supplemental approval covering lisinopril use within 24 hours of acute MI. At 6 weeks, lisinopril 5 mg up-titrated to 10 mg once daily significantly reduced combined death and severe ventricular dysfunction compared with open control (GISSI-3, Lancet 1994). The approved label reflected this narrow initiation window: treatment must begin within 24 hours of symptom onset, and the drug should be discontinued after 6 weeks in patients who did not develop LV dysfunction or heart failure.

Major Label Revisions and Safety Communications

The FDA has issued multiple label changes to both branded NDAs and, by extension, all ANDA holders since 1987. The most consequential revisions are documented below.

2003: Fetal Toxicity Boxed Warning

Before 2003, the pregnancy risk was distributed across the label under "Warnings" and "Precautions." The FDA's safety review of ACE inhibitor-associated fetal and neonatal morbidity data, including cases of oligohydramnios, neonatal renal failure, skull hypoplasia, and death, prompted a formal boxed warning. The revised label states:

"When pregnancy is detected, discontinue lisinopril as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus."

This language applies to all ACE inhibitors and was part of a class-wide labeling update coordinated across multiple NDA holders simultaneously.

2008: Pediatric Hypertension Dosing Added

Following pediatric studies submitted under the Best Pharmaceuticals for Children Act (BPCA), the FDA added dosing guidance for children aged 6 to 16 years with hypertension. The approved pediatric starting dose is 0.07 mg/kg once daily, up to 5 mg, with titration as tolerated. Children with glomerular filtration rates below 30 mL/min/1.73 m² are excluded from this indication due to insufficient safety data.

2012: Intestinal Angioedema Added to Warnings

Post-market case reports through the FDA Adverse Event Reporting System (FAERS) had accumulated sufficient signal to warrant a specific mention of intestinal angioedema as a distinct clinical presentation. Patients who develop abdominal pain on ACE inhibitors should be evaluated for intestinal angioedema even in the absence of facial or laryngeal swelling. This addition changed diagnostic pathways at emergency departments managing acute abdominal pain in patients taking lisinopril.

2014 to 2019: Drug Interaction Updates

Between 2014 and 2019, the label received iterative updates for three interaction categories. Co-administration with sacubitril (as in the fixed-dose combination sacubitril/valsartan, brand name Entresto) was added as a contraindication because the combination substantially raises angioedema risk. The interaction with mTOR inhibitors (temsirolimus, everolimus, sirolimus) was elevated from a precaution to a warning for the same reason. The label update for lithium toxicity risk was also strengthened, noting that serum lithium levels may increase to toxic concentrations when lisinopril is added to stable lithium therapy.

ALLHAT: The Outcomes Trial That Shaped a Generation of Labels

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) remains the largest randomized hypertension outcomes trial ever conducted. Published in JAMA in 2002, ALLHAT enrolled 33,357 high-risk hypertensive adults aged 55 or older and randomly assigned them to chlorthalidone 12.5 to 25 mg, amlodipine 2.5 to 10 mg, or lisinopril 10 to 40 mg once daily (JAMA 2002, PMID 12479763).

Primary Outcomes

The primary composite outcome was fatal coronary heart disease or nonfatal MI. At a mean follow-up of 4.9 years, event rates were 11.5% for chlorthalidone, 11.3% for amlodipine, and 11.4% for lisinopril. The differences were not statistically significant. Lisinopril was non-inferior to the comparators on all-cause mortality.

Secondary Findings With Regulatory Implications

ALLHAT did identify secondary differences that influenced prescribing guidance. The lisinopril arm showed higher rates of stroke (6.3% vs. 5.6% for chlorthalidone, P=0.02) and combined cardiovascular disease events in Black participants. The FDA did not mandate a label change based solely on these secondary findings, but the ACC/AHA hypertension guidelines incorporated ALLHAT data into their recommendation to prefer thiazide diuretics or calcium channel blockers as first-line agents in Black patients without compelling indications for ACE inhibitors.

Blood Pressure Control Differential

A secondary analysis noted that blood pressure control was slightly less effective with lisinopril in Black participants (33.4% controlled vs. 40.2% for chlorthalidone). This physiologic difference, attributed to lower renin activity on average in Black patients, had been recognized clinically before ALLHAT but gained its most strong epidemiologic quantification in this trial.

Generic Market Entry and ANDA Field

Lisinopril's original patents expired in the mid-1990s, making it one of the earliest ACE inhibitors to face generic competition. The first ANDAs were approved in 1995. By the FDA's most recent Orange Book update in 2024, more than 60 manufacturers hold approved ANDAs for at least one strength of lisinopril tablets.

Bioequivalence Standards

All ANDA holders must demonstrate bioequivalence to the reference listed drug using standard pharmacokinetic endpoints (AUC and Cmax within the 80 to 125 percent confidence interval). Because lisinopril is a BCS Class III compound (high solubility, low permeability), in vitro dissolution data play a supporting role but in vivo studies remain the regulatory standard.

Authorized Generics

Both Prinivil and Zestril have been marketed as authorized generics at various points since patent expiration. Authorized generics use the brand manufacturer's NDA directly, meaning no separate ANDA is required and they share the exact formulation of the reference listed drug.

Post-Market Surveillance and FAERS Signal History

The FDA's Sentinel System and FAERS database have generated several lisinopril-related safety signals since 1987. The most clinically significant are summarized here.

Cough Incidence

Dry, persistent cough occurs in approximately 10 to 15% of patients taking ACE inhibitors, with higher rates reported in Asian populations (up to 30 to 40%). This signal was identified in early post-market surveillance and has been a mandatory disclosure in every version of the label since the early 1990s. The mechanism is bradykinin accumulation; ARBs do not share this adverse effect, which has been a primary driver of switching from lisinopril to drugs like losartan or valsartan in intolerant patients.

Angioedema

Angioedema affects approximately 0.1 to 0.7% of ACE inhibitor users. Black patients face a risk three to five times higher than white patients. The FDA has cited FAERS data in multiple safety communications reinforcing that ACE inhibitor-associated angioedema can occur after years of uneventful therapy, not only at initiation. The label instructs immediate discontinuation if angioedema occurs and specifies that patients with a prior episode must never receive another ACE inhibitor.

Hyperkalemia Risk

Hyperkalemia risk is elevated when lisinopril is co-administered with potassium-sparing diuretics, potassium supplements, or trimethoprim-containing antibiotics. FDA Sentinel analyses of large claims databases have confirmed that the trimethoprim interaction produces clinically significant hyperkalemia at a measurable population level, reinforcing the label's drug interaction section.

A Practical Signal-Triage Framework for Clinicians

The following four-step framework organizes the most common lisinopril safety signals by urgency:

1. Immediate discontinuation required: angioedema (facial, laryngeal, intestinal), symptomatic hypotension with serum creatinine rise greater than 30% above baseline, pregnancy confirmed at any stage.
2. Dose reduction or temporary hold: hyperkalemia above 5.5 mEq/L, acute kidney injury with GFR decline greater than 30% from baseline, hypotension with systolic below 90 mmHg in heart failure patients being up-titrated.
3. Monitor and document: dry cough without respiratory compromise (offer ARB switch at patient request), serum creatinine rise of 10 to 30% from baseline within 2 weeks of initiation (acceptable and expected in renovascular disease patients, warrants monitoring, not automatic discontinuation).
4. Reassurance and education only: first-dose hypotension in volume-replete patients on low starting doses (2.5 to 5 mg), mild transient dizziness.

Current Approved Indications and Dosing Summary

As of the most recent FDA-approved prescribing information, lisinopril carries three approved indications.

Hypertension

Starting dose is 10 mg once daily in adults not on diuretics, with a maintenance range of 20 to 40 mg once daily. Patients already on a diuretic should start at 5 mg to reduce first-dose hypotension risk. For patients with creatinine clearance below 30 mL/min but above 10 mL/min, start at 5 mg. For patients on dialysis, start at 2.5 mg.

Heart Failure

Starting dose is 2.5 to 5 mg once daily, with titration to a target of 40 mg once daily as tolerated. The label specifies that blood pressure, renal function, and serum electrolytes should be monitored after each dose increase.

Acute Myocardial Infarction

Initial dose is 5 mg within 24 hours of onset, then 5 mg at 24 hours, 10 mg at 48 hours, and 10 mg once daily for 6 weeks. In patients with systolic below 120 mmHg at presentation, start at 2.5 mg to reduce hypotension risk. The drug should be discontinued after 6 weeks unless heart failure or LV dysfunction is documented.

Guideline Positioning: Where Lisinopril Sits Today

The 2017 ACC/AHA Hypertension Guidelines (endorsed by nine major societies) identify ACE inhibitors as one of four preferred first-line drug classes alongside ARBs, thiazide diuretics, and dihydropyridine calcium channel blockers (ACC/AHA 2017, PMID 29133356). Lisinopril is the most prescribed ACE inhibitor in the United States, appearing on the WHO Model List of Essential Medicines.

The 2022 AHA/ACC Heart Failure Guidelines recommend ACE inhibitors (lisinopril included) as Class I, Level A therapy for patients with HFrEF (EF below 40%), with the goal of achieving the maximum tolerated dose rather than a fixed target (AHA/ACC 2022, PMID 35379503).

For patients who develop intolerable cough on lisinopril, guidelines uniformly recommend switching to an ARB rather than discontinuing the renin-angiotensin system blockade entirely, since the cardiovascular mortality benefit is a class effect tied to neurohormonal blockade, not to any property unique to ACE inhibitors.

How to Access the Current FDA Label

The most current FDA-approved prescribing information for lisinopril is accessible through Drugs@FDA. Clinicians can search either NDA 019777 (Prinivil) or NDA 019898 (Zestril), or access any of the approved ANDA labels through the Orange Book at accessdata.fda.gov. Labels for generic formulations must be therapeutically equivalent to the reference listed drug's current labeling, meaning all boxed warnings, contraindications, and updated interaction data apply equally across all manufacturers.

The FDA's DailyMed database at dailymed.nlm.nih.gov provides the most up-to-date structured product labels in searchable format, including version history, which allows clinicians and pharmacists to compare the current label against any prior version.